TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29768524

Group type: EXPERIMENTAL
Intervention: 2 layers of PRF membranes + CAF (test group-1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4 layers of PRF membranes + CAF (test group-2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CTG + CAF (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PRF membrane + CAF technique
Number of subjects: 63
Study: 1481500

Group type: EXPERIMENTAL
Intervention: Uvesorb
Number of subjects: 96
Study: 22040840

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20422436

Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 273

Group type: COMPARATOR
Intervention: Side to end anastomosis (STEA)
Number of subjects: 273
Study: 18760135

Group type: EXPERIMENTAL
Intervention: Atrial Overdrive Pacing ON (AOP ON)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Atrial Overdrive Pacing OFF (AOP OFF)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: AOP ON
Number of subjects: 409

Group type: COMPARATOR
Intervention: AOP OFF
Number of subjects: 409
Study: 15870187

Group type: EXPERIMENTAL
Intervention: Ocinaplon (total daily dose of 180-240 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12676074

Group type: EXPERIMENTAL
Intervention: Ben 10 mg/d, po
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Val 80 mg/d, po
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Val 80 mg/d + Ben 10 mg/d, po
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (20 normal subjects)
Number of subjects: 90
Study: 10655910

Group type: EXPERIMENTAL
Intervention: Acoustic monitoring (MIC)
Number of subjects: 25
Study: 9125796

Group type: EXPERIMENTAL
Intervention: Current therapeutic modalities for RPGN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging therapeutic options for RPGN
Number of subjects: 0
Study: 1829372

Group type: EXPERIMENTAL
Intervention: 200 micrograms h‐ANP 99‐126 intravenously for 30 min during placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 mg carbidopa every 8 h during ANP infusion
Number of subjects: 10
Study: 6421344

Group type: EXPERIMENTAL
Intervention: BCNU, cyclophosphamide, and prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active drug regimen (sodium fluoride, vitamin D, calcium gluconate, fluoxymesterone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 0
Study: 30788777

Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pulpotomy
Number of subjects: 74
Study: 29880047

Group type: EXPERIMENTAL
Intervention: SMI Patient‐Aligned Care Team (SMI PACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27253829

Group type: EXPERIMENTAL
Intervention: MDMA administration in CYP2D6 poor metabolizers
Number of subjects: 139
Study: 24184589

Group type: EXPERIMENTAL
Intervention: Swimming warm-up plus IME warm-up (2 sets of 30 breaths with a 40% maximum inspiratory mouth pressure load)
Number of subjects: 15

Group type: COMPARATOR
Intervention: IME-only warm-up (2 sets of 30 breaths with a 40% maximum inspiratory mouth pressure load)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Swimming warm-up only
Number of subjects: 15
Study: 22072272

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment 3×/wk during radiotherapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study: 20466163

Group type: EXPERIMENTAL
Intervention: Premix insulin (biphasic insulin aspart 30 [NovoMix 30])
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin detemir [Levemir])
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Meal-time insulin (insulin aspart [NovoRapid])
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: All insulin analogs
Number of subjects: 60000
Study: 17676985

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 18830034

Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonates
Number of subjects: 0
Study: 15182119

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for three continuous hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard NICU care
Number of subjects: 24
Study: 11329231

Group type: EXPERIMENTAL
Intervention: Troglitazone, 400 mg/d
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9291302

Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (single dose at 1 month after transplantation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (three doses at 1, 2, and 3 months after transplantation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (three doses)
Number of subjects: 75
Study: 8409112

Group type: EXPERIMENTAL
Intervention: ONO-1078, 150 mg capsule, administered every 12 hours for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, inactive, administered every 12 hours for 1 week
Number of subjects: 0
Study: 3516203

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11555165

Group type: EXPERIMENTAL
Intervention: 60‐Hz magnetic fields at an intensity of 28.3 microTesla (microT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham exposure under equivalent, counter‐balanced, no‐exposure (<= 0.2 microT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 60‐Hz magnetic fields
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 46
Study: 30142300

Group type: EXPERIMENTAL
Intervention: MI‐SafeCope
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 36
Study: 29444611

Group type: EXPERIMENTAL
Intervention: Goreisan (7.5 g daily for 12 weeks)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 180
Study: 27554053

Group type: EXPERIMENTAL
Intervention: Escherichia coli LPS (2 ng/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Transdermal nicotine patch (applied 10 hours previously)
Number of subjects: 17
Study: 24617755

Group type: EXPERIMENTAL
Intervention: Nurse-led case management programme
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study: 22549090

Group type: EXPERIMENTAL
Intervention: GTU(®)-Multi-HIVB vaccine (1mg/dose IM at 0, 4, 12 weeks, boosted at 76 and 80 weeks with 2mg/dose)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19733353

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17276548

Group type: EXPERIMENTAL
Intervention: Oral indomethacin/acetaminophen combination therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral prednisolone/acetaminophen combination therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study: 16198660

Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939 (1.25‐‐80 mg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939 (5‐mg tablet and oral solution)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 12189361

Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg oral administration)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HIV/CMV-positive patients
Number of subjects: 44
Study: 10321486

Group type: EXPERIMENTAL
Intervention: Part-to-whole face processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Part-to-part face processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole faces and isolated eyes
Number of subjects: 0
Study: 8849180

Group type: EXPERIMENTAL
Intervention: Doxycycline plus ketoprofen (doxycycline 100 mg twice daily for 10 days plus ketoprofen 200 mg daily for 10 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 10 days)
Number of subjects: 65
Study: 2216372

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonrigid fixation
Number of subjects: 40
Study: 100202

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (4500 rad over five weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study: 31561728

Group type: EXPERIMENTAL
Intervention: Resistance Training Group (TG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 25
Study: 30043183

Group type: EXPERIMENTAL
Intervention: Compression socks (SOCK, n=34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CONTROL, n=33)
Number of subjects: 67
Study: 26991494

Group type: EXPERIMENTAL
Intervention: BoNT/A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/A-B
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 12
Study: 25198268

Group type: EXPERIMENTAL
Intervention: Random biopsy
Number of subjects: 388
Study: 21733319

Group type: EXPERIMENTAL
Intervention: Pistachio nuts (0, 42, and 84 g/d)
Number of subjects: 16
Study: 21148614

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg) once daily
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 889
Study: 17320313

Group type: EXPERIMENTAL
Intervention: Smoking the first cigarette of the day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Greater decreases in craving as measured by the QSU‐Brief
Number of subjects: 207
Study: 15780846

Group type: COMPARATOR
Intervention: 0 mg Delta‐9‐THC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.5 mg Delta‐9‐THC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 5 mg Delta‐9‐THC
Number of subjects: 13
Study: 12860330

Group type: EXPERIMENTAL
Intervention: Current smokers at conception
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Current smokers reporting <15 cigarettes per day
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Current smokers reporting >=15 cigarettes per day
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Women who quit smoking 1 year or more before conception
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked during the first trimester of pregnancy
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Partner's smoking
Number of subjects: 1437
Study: 10832257

Group type: EXPERIMENTAL
Intervention: 4 percent articaine with epinephrine 1:100,000
Number of subjects: 1325

Group type: COMPARATOR
Intervention: 2 percent lidocaine with epinephrine 1:100,000
Number of subjects: 1325
Study: 8857500

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.025%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.05%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.75%
Number of subjects: 0
Study: 1996738

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6mg/kg per day for 12 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ivermectin 400 mcg/kg (200 mcg/kg per day for 2 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ivermectin (1 mg oral dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 30
Study: 6340972

Group type: EXPERIMENTAL
Intervention: Fentiazac 400 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulindac 200 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentiazac
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentiazac (long-term tolerance study)
Number of subjects: 40
Study: 29505867

Group type: EXPERIMENTAL
Intervention: HOMBRE intervention (culturally adapted intervention providing individual choice of self‐directed online videos, coach‐facilitated in‐person groups, and coach‐facilitated online groups)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Minimal intensity intervention (uses online videos with a coach available, if solicited by the participant)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: HOMBRE intervention
Number of subjects: 424
Study: 26718792

Group type: EXPERIMENTAL
Intervention: Silexan 80mg
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 25245218

Group type: EXPERIMENTAL
Intervention: CCRT with 20 mg/m2 cisplatin for 5 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: RT
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 192
Study: 21848925

Group type: EXPERIMENTAL
Intervention: Internet-based blood glucose monitoring system (submitted weekly for 6 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (routine follow-up, no submission of blood glucose levels)
Number of subjects: 70
Study: 20348185

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Education in Successful Aging (SA)
Number of subjects: 30
Study: 17440420

Group type: EXPERIMENTAL
Intervention: Liberal transfusion threshold (10 g/dL hemoglobin)
Number of subjects: 1699

Group type: COMPARATOR
Intervention: Restrictive transfusion threshold (7 g/dL hemoglobin)
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 1699

Group type: COMPARATOR
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 1699
Study: 15629618

Group type: EXPERIMENTAL
Intervention: Head mask (HM)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Head-and-shoulder mask (HSM)
Number of subjects: 260
Study: 12384647

Group type: EXPERIMENTAL
Intervention: L-arginine (L-A) infusion at a rate of 1.5 g/min for 20 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study: 9563145

Group type: EXPERIMENTAL
Intervention: Dibenyline 10 mg b.i.d. (n = 71)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg q.d. (n = 54)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combination of dibenyline and finasteride (n = 65)
Number of subjects: 190
Study: 7826784

Group type: EXPERIMENTAL
Intervention: Sevoflurane (up to 7%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Halothane (up to 3.5%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 50
Study: 3415462

Group type: EXPERIMENTAL
Intervention: Arterial reconstruction (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CA ligation or non‐operative management (group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonocclusive injuries managed nonoperatively (group 3)
Number of subjects: 80
Study: 31684943

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) implementation with external expert support (5 days provided)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) implementation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) training
Number of subjects: 42
Study: 29790479

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES; Ultimaster)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES; XIENCE)
Number of subjects: 1101
Study: 27630504

Group type: EXPERIMENTAL
Intervention: Perio Q(TM) gel + SRP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: tea tree oil gel + SRP
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo gel + SRP
Number of subjects: 15
Study: 24995473

Group type: EXPERIMENTAL
Intervention: Silicone impressions
Number of subjects: 85

Group type: COMPARATOR
Intervention: Alginate impressions
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both impressions
Number of subjects: 85
Study: 23249098

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for 32 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for 20 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 21041813

Group type: EXPERIMENTAL
Intervention: 9 g/d oligofructose-enriched inulin in a calcium-fortified cereal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control cereal with no inulin
Number of subjects: 14
Study: 16616075

Group type: EXPERIMENTAL
Intervention: Implicit perceptual information on object colour during sentence comprehension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching colour condition
Number of subjects: 0
Study: 15720735

Group type: EXPERIMENTAL
Intervention: FTIR‐ATR analysis of hair from breast cancer patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: FTIR‐ATR analysis of hair from healthy subjects
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blind study using FTIR‐ATR spectral differences as markers
Number of subjects: 32
Study: 11914244

Group type: EXPERIMENTAL
Intervention: Strain rate imaging (SRI) postablation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strain rate imaging (SRI) comparing infarct and noninfarct areas
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) pre- and postablation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) comparing infarct and noninfarct areas
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SRI analysis
Number of subjects: 10
Study: 9730069

Group type: EXPERIMENTAL
Intervention: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.113 mg/cm2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.225 mg/cm2
Number of subjects: 23
Study: 8137516

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH-releasing hormone 1 microgram/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH-releasing hormone without dexamethasone pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8
Study: 2605801

Group type: EXPERIMENTAL
Intervention: 4 mg of perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg of perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril
Number of subjects: 0
Study: 1159330

Group type: COMPARATOR
Intervention: Gentamicin sulfate (1.5 mg/kg) intravenous injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Gentamicin sulfate (1.5 mg/kg) intramuscular injection
Number of subjects: 6
Study: 7362050

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 54
Study: 31605587

Group type: EXPERIMENTAL
Intervention: Opioid-Free General Anesthesia (OFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General balanced anesthesia with fentanyl (F group - FG)
Number of subjects: 60
Study: 28678332

Group type: EXPERIMENTAL
Intervention: Strength group (oral hypoglycemic medications, subcutaneous insulin infusion, or continuous infusion by micropump)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mitigation group (personalized treatment programs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (diet and exercise)
Number of subjects: 90
Study: 26047470

Group type: EXPERIMENTAL
Intervention: Treatment group (specific intervention not detailed)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Whites
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Blacks
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Participants with hemoglobin A1c < 7.0%
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Participants who did not maintain glycemic control at 6 months
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: MetS classifications
Number of subjects: 679
Study: 23422399

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 21551998

Group type: EXPERIMENTAL
Intervention: Carbonated water intake
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tap water intake (Control)
Number of subjects: 40
Study: 18390917

Group type: EXPERIMENTAL
Intervention: Treadmill and cycling exercise (30‐90 min, three to five times per week) at a HR corresponding to 50% of peak oxygen uptake (VO2peak)
Number of subjects: 326
Study: 17342002

Group type: EXPERIMENTAL
Intervention: Web-based educational and HF management program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 40
Study: 15087793

Group type: EXPERIMENTAL
Intervention: Solid arthrodesis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pseudarthrosis
Number of subjects: 47
Study: 11834234

Group type: EXPERIMENTAL
Intervention: Leios (0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stediril 30 (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study: 9609624

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.8 mg
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study: 7825009

Group type: EXPERIMENTAL
Intervention: Indirect enzyme‐linked immunosorbent assay (ELISA) using 31.5 kDa antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoblot analysis using 31.5 kDa antigen
Number of subjects: 0